Please assess the completion status of the following clinical trial:

Trial Title: A Study of Sativex® for Pain Relief in Patients With Advanced Malignancy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Willing and able to give informed consent.~* Male or female, age 18 years or above.~* Diagnosed with cancer of any type, which is considered to be terminal.~* Diagnosed with cancer-related pain which is not wholly alleviated with their current strong opioid treatment and whose level of pain measured on a NRS is ³four on at least one occasion per day, during the two day run-in period, leading up to visit 1.~* On strong opioid maintenance therapy for at least seven days prior to the screening visit.~* Willing to abstain from any use of cannabis during the study, other than the study medication.~* No cannabinoids use (cannabis, Marinol® or Nabilone) for at least seven days before Visit 1 and willing to abstain from any use of cannabis during the study.~* Clinically acceptable blood results at the screening visit.~* Able (in the investigators opinion) and willing to undertake and comply with all study requirements.~* Willing to allow their own general practitioner, and consultant if appropriate, to be informed of study participation.~* Willing for the Home Office to be notified of his or her participation in the study (applicable to the UK centres only).~Exclusion Criteria:~* Know history of substance misuse.~* Known or suspected to have had an adverse reaction to cannabinoids causing psychosis or other severe psychiatric illness.~* Received any epidural analgesia within 48 hours prior to study entry.~* Either received, within two weeks of study entry, or due to receive chemotherapy or radiotherapy during the study.~* Unable to give informed consent.~* History of any type of schizophrenia, any other psychotic illness, a serious personality disorder, or other significant psychiatric illness other than depression associated with their chronic pain and/or in response to the underlying condition.~* Currently taking levodopa (Sinemet®, Sinemet plus®, Levodopa®, L-dopa®, Madopar®, Benserazide®).~* Had a serious cardiovascular disorder, including angina, uncontrolled hypertension, or an uncontrolled symptomatic cardiac arrhythmia.~* Significant renal or hepatic impairment, who in the opinion of the investigator, were unsuitable for treatment with study medication.~* History of epilepsy.~* Had oral cavity cancers or whose previous treatments had included radiotherapy to the floor of the mouth.~* Female subjects who were pregnant or lactating or of child-bearing potential and were inadequately protected against conception during the study and for three months thereafter.~* Male subjects who were sexually active and who were not using adequate forms of contraception during the study and for three months thereafter.~* Subjects who had participated in a clinical research study in the past four weeks, prior to study entry.~* Planned travel outside the UK during the study (applicable to the UK centres only).~* Subjects who, in the opinion of the investigator, were unsuitable to participate in the study for any other reason, not mentioned in the entry criteria.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Placebo (Type: PLACEBO_COMPARATOR): Placebo control
- Sativex (Type: EXPERIMENTAL): Active treatment
- THC Alone (Type: EXPERIMENTAL): Active treatment

Based on this trial design, predict the completion outcome and termination type (if applicable).